BenevolentAI Bio   Report issue

For profit Phase 1 Phase 2
Founded: London United Kingdom (2013)

Organization Overview

First Clinical Trial
2017
NCT03194217
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

BenevolentAI Bio